Resources Learning Center MHC Class I & Class II Tetramers T cell detection / Immunology Research
T cell detection / Immunology Research
Peer-reviewed Publications
Publications citing products for T-cell detection
MBL International is renowned in the life sciences industries for high quality and trusted reagents. We are proud to highlight ground breaking research. Find peer reviewed publications/citations for MBL products below. If you published using one of our products, please let us know!
Looking for publications on all other MBLI products/reagents? Click here!
Research/Disease Areas
Infectious Diseases |
Cancer |
Mouse Models |
NKT Cells |
Non-human Primate Models |
Controls |
| CMV | Survivin | OVA | CD1d | SIV | Negative tetramer |
| EBV | MART |
MuLV |
|||
| HIV | Her-2 | hy uty | |||
| Influenza | ESAT | CEA | |||
| SARS | WT1 | ||||
| RSV | Tyrosine | ||||
| HTLV |
| Shin, Hocheol, Yujin Kim, and Sangyong Jon. “Nanovaccine displaying immunodominant T cell epitopes of fibroblast activation protein is effective against desmoplastic tumors.” ACS nano (2023). 10.1021/acsnano.3c00764 |
| Saotome, K., Dudgeon, D., Colotti, K. et al. Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM. Nat Commun 14, 2401 (2023). doi:10.1038/s41467-023-37532-7 |
| Bruno, Peter M., et al. “High-Throughput, Targeted MHC Class I Immunopeptidomics Using a Functional Genetics Screening Platform.” Nature Biotechnology, 2023, doi:10.1038/s41587-022-01566-x. |
| Son, Eric T., et al. “Screening Self-Peptides for Recognition by Mouse Alloreactive cd8+ T Cells Using Direct Ex Vivo Multimer Staining.” STAR Protocols, vol. 4, no. 1, 2023, p. 101943., doi:10.1016/j.xpro.2022.101943. |
| Ogura, Hideki, et al. “DYSFUNCTIONAL SARS-COV-2-M Protein-Specific Cytotoxic T Lymphocytes in Patients Recovering from Severe COVID-19.” Nature Communications, vol. 13, no. 1, 2022, doi:10.1038/s41467-022-34655-1. |
| Wang, Sizhen, et al. “Expansion of KRAS Hot Spot Mutations Reactive T Cells from Human Pancreatic Tumors Using Autologous T-Cells as the Antigen-Presenting Cells.” 2022, doi:10.21203/rs.3.rs-1944651/v1. |
| Zhang, Xiaoyan, et al. “Single-Cell Sequencing Reveals cd133+cd44−-Originating Evolution and Novel STEMNESS Related Variants in Human Colorectal Cancer.” EBioMedicine, vol. 82, 2022, p. 104125., doi:10.1016/j.ebiom.2022.104125. |
| Hikichi, T., Sakamoto, M., Harada, M., Saito, M., Yamane, Y., Tokumura, K., & Nakamura, Y. (2022). Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides. Journal of Human Genetics. https://doi.org/10.1038/s10038-022-01013-4 |
| Dong et al., Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma, Cancer Cell (2021), https://doi.org/10.1016/j.ccell.2021.12.006 |
| Zhang, SM., Cai, W.L., Liu, X. et al. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature 598,682–687 (2021). Available at: https://doi.org/10.1038/s41586-021-03994-2 |
| Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug. Available at https://ar.iiarjournals.org/content/41/8/4101.abstract#sec1ps://ar.iiarjournals.org/content/41/8/4101.abstract#sec-1 |
| Sydney X. Lu, Emma de Neef, James D. Thomas, Luis Diaz, Jr., Omar Abdel-Wahab, Robert K. Bradley. (2021) Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 12066. Available at: /https://www.sciencedirect.com/science/article/abs/pii/S0092867421006905 |
| Hu, C., Shen, M., Han, X., Chen, Q., Li, L., Chen, S., . . . Jin, A. (2021). Identification of Cross-Reactive CD8 T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants. Genes & Diseases. Available at: https://www.sciencedirect.com/science/article/pii/S2352304221000842 |
| Han, J., Yu, R., Duan, J., Li, J., Zhao, W., Feng, G., . . . Wang, J. (2021). Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers. Science Advances, 7(21). Available at: https://advances.sciencemag.org/content/7/21/eabd6971 |
| Teng Wei, Matthias Leisegang, Ming Xia, Kazuma Kiyotani, Ning Li, Chenquan Zeng, Chunyan Deng, Jinxing Jiang, Makiko Harada, Nishant Agrawal, Liangping Li, Hui Qi, Yusuke Nakamura & Lili Ren (2021) Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma, OncoImmunology, 10:1, Available at: https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1929726 |
| Poluektov, Y., Daftarian, P., & Delcommenne, M. C. (2020). Assessment of SARS-CoV-2 Specific CD4( ) and CD8 ( ) T Cell Responses Using MHC Class I and II Tetramers. Biorxiv Available at: https://www.biorxiv.org/content/10.1101/2020.07.08.194209v1://www.biorxiv.org/content/10.1101/2020.07.08.194209v1 |
| Son, E. T., Faridi, P., Paul-Heng, M., Leong, M., English, K., Ramarathinam, S. H., . . . Sharland, A. F. (2020). The self-peptide repertoire plays a critical role in transplant tolerance induction. Biorxiv. Available at: https://whttps://www.biorxiv.org/content/10.1101/2020.11.09.359968v2ww.biorxiv.org/content/10.1101/2020.11.09.359968v2 |
| Zhang, Y., Zhang, J., Chen, Y., Luo, B., Yuan, Y., Huang, F., . . . Zhang, H. (2020). The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I. Biorxiv. Available at: https://www.biorxiv.org/content/10.1101/2020.05.24.111823v1/www.biorxiv.org/content/10.1101/2020.05.24.111823v1 |
| Najafabadi, A. H., Zhang, J., Aikins, M. E., Abadi, Z. I., Liao, F., Qin, Y., Moon, J. J. (2020). Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs. Nano Letters, 20(10), 7783-7792. Available at: https://pubs.acs.org/doi/10.1021/acs.nanolett.0c03414://pubs.acs.org/doi/10.1021/acs.nanolett.0c03414 |
| Song, X., Lu, Z., & Xu, J. (2020). Targeting cluster of differentiation 47 improves the efficacy of anti‑cytotoxic T‑lymphocyte associated protein 4 treatment via antigen presentation enhancement in pancreatic ductal adenocarcinoma. Experimental and Therapeutic Medicine. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444377/s://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444377/ |
| Lo, W., Parkhurst, M., Robbins, P. F., Tran, E., Lu, Y., Jia, L., . . . Rosenberg, S. A. (2019). Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. Cancer Immunology Research, 7(4), 534-543 Available at: https://cancerimmunolres.aacrjournals.org/content/7/4/534 |
| Dustin, M. L., & Mayya, V. (2019). Faculty Opinions recommendation of T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. Available at: https://pubmed.ncbi.nlm.nih.gov/31398327/ |
| Smith, C. C., Chai, S., Washington, A. R., Lee, S. J., Landoni, E., Field, K., . . . Vincent, B. G. (2019). Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Cancer Immunology Research, 7(10), 1591-1604. Available at: https://cancerimmunolres.aacrjournals.org/content/7/10/1591.full-text.pdfps://cancerimmunolres.aacrjournals.org/content/7/10/1591.full-text.pdf |
| Marc C Delcommenne, Olga Hrytsenko, Cynthia Tram, Genevieve Weir and Marianne M. Stanford. (2017) The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine. J Immunol, 198 (1 Supplement) 79.27 Available at: https://www.jimmunol.org/content/198/1_Supplement/79.27://www.jimmunol.org/content/198/1_Supplement/79.27 |
| HLA-A:02*01 | Shacklett BL, et al. J Virol 77: 5621-5631 (2003, BCI) |
| Aandahl EM, et al. J Immunol 170: 2349-2355 (2003 BCI) | |
| Betts MR, et al. J Immunol 172: 6407-6417 (2004, BCI) | |
| Paczesny S, et al. J Exp Med 199: 1503-1511 (2004 BCI) | |
| Morita Y, et al. Bone Marrow Transplant 36: 803-811 (2005) | |
| Komatsu H, et al. Immun Ageing 3: 11 (2006) | |
| Comin-Anduix B, et al. Clin Cancer Res 12: 107-116 (2006, BCI) | |
| Zhang H, et al. J Immunol 179: 4910-4918 (2007 BCI) | |
| Sabouri AH, et al. Blood 112: 2411-2420 (2008) | |
| Watanabe K, et al. Int J Hematol. 88: 311-320 (2008) | |
| Walker EB, et al. Clin. Cancer Res 14: 5270-5283 (2008 BCI) | |
| Harari A, et al. J Virol 83: 2862-2871 (2009 BCI) | |
| Cellerai C, et al. J Virol 84: 3868–3878 (2010 BCI) | |
| Alanio C, et al. Blood 115: 3718-3725 (2010 BCI) | |
| Takamori A, et al. Retrovirology 8: 100 (2011) | |
| Odumade OA, et al. J Exp Med 209: 471-478 (2012 BCI) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) | |
| Nakauchi Y, et al. Exp Hematol 43: 79–88 (2015, MBL) | |
|
HLA-B*08:01, HLA-B*35:01 |
Odumade OA, et al. J Exp Med 209: 471-478 (2012 BCI) |
|
H-2Db |
Mumprecht S, et al. Blood 113: 4681-4689 (2009, BCI) |
| Ohyagi H, et al. Immunity 39: 584-598 (2013) |
| HLA-A:02*01 | Tomiyama M, et al. Anticancer Res. 24: 3327-3334 (2004) |
| Sasawatari S, et al. Immunol Cell Biol 84: 512–521 (2006, MBL) | |
| Turtle CJ, et al. Immunity 31: 834-844 (2009 BCI) | |
| Harari A, et al. J Virol 83: 2862-2871 (2009 BCI) | |
| Shultz LD, et al. PNAS 107: 13022-13027 (2010) | |
| Cellerai C, et al. J Virol 84: 3868–3878 (2010 BCI) | |
| Odumade OA, et al. J Exp Med 209: 471-478 (2012 BCI) | |
| Faustman DL, et al. PLoS One 7: e41756 (2012, BCI) | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
|
Shultz LD, et al. PNAS 107: 13022-13027 (2010) |
|
| Sasawatari S, et al. Immunol Cell Biol 84: 512–521 (2006, MBL) | |
| HLA-A:24*02 | Watanabe K, et al. Int J Hematol. 88: 311-320 (2008) |
| Kozako T, et al. Leukemia 23: 375-382 (2009) , BRLF1 | |
| Sato K, et al. Blood 117: 5663-5673 (2011) | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) , BRLF1 | |
| ts-m002-1 brlf1 | |
| Watanabe K, et al. Int J Hematol. 88: 311-320 (2008) BMLF1 | |
| Kozako T, et al. Leukemia 23: 375-382 (2009) , BRLF1 | |
| Sato K, et al. Blood 117: 5663-5673 (2011) | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) , BRLF1 | |
| Watanabe K, et al. Int J Hematol. 88: 311-320 (2008) BMLF1 | |
| Kozako T, et al. Leukemia 23: 375-382 (2009) , BRLF1 | |
| Sato K, et al. Blood 117: 5663-5673 (2011) | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) , BRLF1 | |
| Watanabe K, et al. Int J Hematol. 88: 311-320 (2008) BMLF1 | |
| Kozako T, et al. Leukemia 23: 375-382 (2009) , BRLF1 | |
| Sato K, et al. Blood 117: 5663-5673 (2011) | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) , BRLF1 | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
| HLA-B:08*01 | Cellerai C, et al. J Virol 84: 3868–3878 (2010 BCI) |
| HLA-A:02*01 | Shacklett BL, et al. J Virol 77: 5621-5631 (2003, BCI) |
| Harari A, et al. J Virol 83: 2862-2871 (2009 BCI) | |
| Cellerai C, et al. J Virol 84: 3868–3878 (2010 BCI) | |
| Kitamura H, et al. Urology 67: 955-959 (2006) | |
| Tsuruma T, et al. J Transl Med 6: 24 (2008) | |
| Miyazaki A, et al. Cancer Sci. 102: 324-329 (2011) | |
| Kameshima H, et al. Cancer Sci. 102: 1181-1187 (2011) | |
| Kameshima H, et al. Cancer Sci. 104: 124-129 (2013) | |
| Satomi F, et al. Int J Cancer Clin Res 2: 1-6 (2015, MBL) | |
| Tanaka T, et al. Cancer Sci. 106: 18-24 (2015) | |
| Tanaka T, et al. Clin Dev Immunol. 2013;2013:262967. doi: 10.1155/2013/262967 |
| HLA-A:02*01 | Mantovani S, et al. J Immunol 169: 6253-6260 (2002 BCI) |
| Aandahl EM. et al. J. Immunol. 170: 2349-2355 (2003 BCI) | |
| Paczesny S, et al. J Exp Med 199: 1503-1511 (2004 BCI) | |
| Coughlin CM, et al. Blood 103: 2046-2054 (2004 BCI) | |
| Hess C, et al. Blood 104: 3463-3471 (2004 BCI) | |
| Aandahl EM, et al. Blood 104: 3672-3678 (2004 BCI) | |
| Akiyama Y, et al. J. Transl. Med. 3: 4-13 (2005) | |
| Moran TP, et al. J Immunol 175: 3431-3438 (2005 BCI) | |
| Cooper LJN, et al. Blood 105: 1622-1631 (2005 BCI) | |
| Yang S, et al. Clin Cancer Res 11: 5603-5615 (2005 BCI) | |
| Naumov YN, et al. J Immunol 177: 2006-2014 (2006 BCI) | |
| Casati C. et al. Cancer Res. 66: 4450-4460 (2006 BCI) | |
| Zhang H, et al. J Immunol 179: 4910-4918 (2007 BCI) | |
| Naumov YN, et al. J Immunol 181: 7407-7419 (2008) | |
| Walker EB, et al. Clin. Cancer Res 14: 5270-5283 (2008 BCI) | |
| He X-S, et al. J Infect Dis 197: 803-811 (2008 BCI) | |
| Yu CI, et al. Blood 112: 3671-3678 (2008 BCI) | |
| Turtle CJ, et al. Immunity 31: 834-844 (2009 BCI) | |
| Frleta D, et al. J. Immunol 182: 2766-2776 (2009 BCI) | |
| Harari A, et al. J Virol 83: 2862-2871 (2009 BCI) | |
| Cellerai C, et al. J Virol 84: 3868–3878 (2010 BCI) | |
| Tu W, et al. J Virol 84: 6527-6535 (2010 BCI) | |
| Ndhlovu ZM, et al. PNAS 107: 3669-3674 (2010 BCI) | |
| Alanio C, et al. Blood 115: 3718-3725 (2010 BCI) | |
| Romano E, et al. Clin Cancer Res 17: 1984-1997 (2011 BCI) | |
| Odumade OA, et al. J Exp Med 209: 471-478 (2012 BCI) | |
| Flamar A-L, et al.J Immunol 189: 2645-2655 (2012 BCI) | |
| Bruns H, et al. Clin Cancer Res 21: 2075-2083 (2015, BCI) |
| Hong, Suyeon, et al. “Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus.” Scientific reports 11.1 (2021): 1-13. | |
| Morabito, Kaitlyn M., et al. “Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung.” Mucosal immunology 10.2 (2017): 545-554. |
| HLA-A:02*01, HLA-A:11*01, HLA-A:24*02 | Kozako T, et al. J Immunol 177: 5718-5726 (2006) |
| Akimoto M, et al. J Med Virol 79: 977-986 (2007) | |
| Sabouri AH, et al. Blood 112: 2411-2420 (2008) | |
| Kozako T, et al. Leukemia 23: 375-382 (2009) | |
| Tanaka Y, et al. Cancer Res 70: 6181-6192 (2010) | |
| Takamori A, et al. Retrovirology 8: 100 (2011) | |
| Kozako T, et al. Hum Immunol 72: 1001-1006 (2011) | |
| Kozako T, et al. J Med Virol 83: 501-509 (2011) | |
| Kozako T, et al. FEBS J 278: 1358–1366 (2011) | |
| Tamai Y, et al. J Immunol 190: 4382-4392 (2013) | |
| Tezuka K, et al. Blood 123: 346-355 (2014) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) | |
| Matsuura E, et al. J Neuropathol Exp Neurol 74: 2-14 (2015) | |
| Kozako T, et al. J Immunol 177: 5718-5726 (2006) | |
| Akimoto M, et al. J Med Virol 79: 977-986 (2007) | |
| Sabouri AH, et al. Blood 112: 2411-2420 (2008) | |
| Kozako T, et al. Leukemia 23: 375-382 (2009) | |
| Tanaka Y, et al. Cancer Res 70: 6181-6192 (2010) | |
| Takamori A, et al. Retrovirology 8: 100 (2011) | |
| Kozako T, et al. Hum Immunol 72: 1001-1006 (2011) | |
| Kozako T, et al. J Med Virol 83: 501-509 (2011) | |
| Kozako T, et al. FEBS J 278: 1358–1366 (2011) | |
| Tamai Y, et al. J Immunol 190: 4382-4392 (2013) | |
| Tezuka K, et al. Blood 123: 346-355 (2014) | |
| Ezinne CC, et al. PLoS One 9: e87631 (2014) | |
| Matsuura E, et al. J Neuropathol Exp Neurol 74: 2-14 (2015) |
| HLA-A:02*01 | Paczesny S, et al. J Exp Med 199: 1503-1511 (2004 BCI) |
| Akiyama Y, et al. J Transl Med 3: 4-13 (2005) | |
| Romano E, et al. Clin Cancer Res 17: 1984-1997 (2011 BCI) | |
| Mehrotra S, et al. J Immunol 189: 1627-1638 (2012 BCI) |
| Chaisawangwong, Worarat, et al. “Cross-reactivity of SARS-CoV-2–and influenza A–specific T cells in individuals exposed to SARS-CoV-2.” JCI insight 7.18 (2022). |
| HLA-A:24*02 | Kitamura H, et al. Urology 67: 955-959 (2006) |
| Tsuruma T, et al. J Transl Med 6: 24 (2008) | |
| Miyazaki A, et al. Cancer Sci. 102: 324-329 (2011) | |
| Kameshima H, et al. Cancer Sci. 102: 1181-1187 (2011) | |
| Kameshima H, et al. Cancer Sci. 104: 124-129 (2013) | |
| Satomi F, et al. Int J Cancer Clin Res 2: 1-6 (2015, MBL) | |
| Tanaka T, et al. Cancer Sci. 106: 18-24 (2015) | |
| Tanaka T, et al. Clin Dev Immunol. 2013;2013:262967. doi: 10.1155/2013/262967 |
| HLA-A:02*01 | Mantovani S, et al. J Immunol 169: 6253-6260 (2002 BCI) |
| Paczesny S, et al. J Exp Med 199: 1503-1511 (2004 BCI) | |
| Coughlin CM, et al. Blood 103: 2046-2054 (2004 BCI) | |
| Tomiyama M, et al. Anticancer Res. 24: 3327-3334 (2004, MBL) | |
| Akiyama Y, et al. J. Transl. Med. 3: 4-13 (2005) | |
| Casati C, et al. Cancer Res 66: 4450-4460 (2006 BCI) | |
| Sasawatari S, et al. Immunol Cell Biol 84: 512–521 (2006, MBL) | |
| Wong RM, et al. Int Immunol 19: 1223-1234 (2007 BCI) | |
| Takahara M, et al. J. Leukoc. Biol. 83: 742-754 (2008) | |
| Frleta D, et al. J. Immunol 182: 2766-2776 (2009 BCI) | |
| Alanio C, et al. Blood 115: 3718-3725 (2010 BCI) | |
| Banchereau J, et al. PNAS 109: 18885-18890 (2012 BCI) | |
| Bruns H, et al. Clin Cancer Res 21: 2075-2083 (2015, BCI) | |
| McCracken MN, et al. J Clin Invest 125: 1815–1826 (2015, MBL) |
| HLA-A:02*01 | Faustman DL, et al. PLoS One 7: e41756 (2012, BCI) |
| I-Ab | Liao T-YA, et al. PLoS ONE 10: e0145833 (2015, MBL) |
| HLA-A:02*01 | Kobayashi M, et al. J Ovarian Res. 7: 48 (2014) |
| Najima Y, et al. Blood 127: 722-734 (2016, MBL) |
| HLA-A:02*01 | Paczesny S, et al. J Exp Med 199: 1503-1511 (2004 BCI) |
| Akiyama Y, et al. J. Transl. Med. 3: 4-13 (2005) | |
| Wong RM, et al. Int Immunol 19: 1223-1234 (2007 BCI) | |
| Walker EB, et al. Clin. Cancer Res 14: 5270-5283 (2008 BCI) | |
| Frleta D, et al. J. Immunol 182: 2766-2776 (2009 BCI) | |
| Romano E, et al. Clin. Cancer Res 17: 1984-1997 (2011 BCI) | |
| Walker EB, et al. Clin. Cancer Res 14: 5270-5283 (2008 BCI) | |
| Chung B, et al. Cell Reports 8: 871-882 (2014 MBLI) | |
| H2-Db | Betts MR, et al. J Immunol 172: 6407-6417 (2004, BCI) |
| Akiyama Y, et al. J. Transl. Med. 3: 4-13 (2005) | |
| Jalili A, et al. Blood 106: 3538-3545 (2005) | |
| Miyagawa N, et al. Oncology 70: 54-62 (2006) | |
| Kozako T, et al. J. Immunol. 177: 5718-5726 (2006) | |
| Santomasso BD, et al. PNAS 104: 19073-19078 (2007 BCI) | |
| Akimoto M, et al. J. Med Virol. 79: 977-86 (2007) | |
| Harao M, et al. Int J Cancer 123: 2616-2625 (2008) | |
| Tsukahara T, et al. Cancer Sci. 99: 368-375 (2008) | |
| Wakabayashi A, et al. J. Immunol.180: 4000-4010 (2008) | |
| Suemori K, et al. J. Gen. Virol. 90: 1806-1811 (2009) | |
| Tsukamoto T, et al. J. Virol. 83: 9339-9346 (2009) | |
| Akiyama Y, et al. Anticancer Res. 29: 647-655 (2009) | |
| Yoshizaki M, et al. Blood 114: 1518-1527 (2009) | |
| Takatsuka N, et al. Int. Immunol. 21: 1089-1100 (2009) | |
| Kobayashi E, et al. Nature Med 19: 1542–1546 (2013) | |
| Suzuki H, et al. J Transl Med 11: 97 (2013) | |
| Tomita Y, et al. OncoImmunology 3: e28100 (2014) | |
| Imamura Y, et al. PLoS ONE 11: e0152384 (2016) | |
| hang, X., Luo, M., Dastagir, S.R. et al. Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. Nat Commun 12, 2637 (2021). |
| H2-Kb | Teramoto K, et al. Cancer Res. 63: 7920-7925 (2003) |
| Li W, et al. Infect. Immun. 72: 7005-7011 (2004) | |
| Yajima T, et al. J. Immunol. 174: 3590-3597 (2005) | |
| Taneichi M, et al. J. Immunol. 177: 2324-2330 (2006) | |
| Wakita D, et al. Int. Immunol. 18: 425-434 (2006) | |
| Chamoto K, et al. Cancer Res. 66: 1809-1817 (2006) | |
| Saito K, et al. J. Immunol. 176: 2496-2504 (2006) | |
| Yokouchi H, et al. Cancer Sci. 97: 148-154 (2006) | |
| Yajima T, et al. J. Immunol. 176: 507-515 (2006) | |
| Nabekura T, et al. Molecular Therapy 13: 301–309 (2006) | |
| Li W, et al. J Immunol 178: 4482-4488 (2007) | |
| Zhang Y, et al. Int Immunol 19: 151-161 (2007) | |
| Kumar H, et al. J Immunol 180: 683-687 (2008) | |
| Wakabayashi A, et al. J Immunol 180: 4000-4010 (2008) | |
| Tang C, et al. J Leukoc Biol 86: 187-194 (2009) | |
| Kijima M, et al. J Immunol 182: 3566-3572 (2009) | |
| Senju S, et al. Stem Cells 27: 1021-31 (2009) | |
| Takeshima T, et al. Cancer Res 70: 2697-2706 (2010) | |
| Asano J, et al. J Immunol 184: 736-745 (2010) | |
| Kuwada E, et al. Anticancer Res 31: 881-891 (2011) | |
| Kurachi S, et al. J Exp Med 208: 1605-1620 (2011) | |
| Yanai H, et al. PNAS 108: 11542-11547 (2011) | |
| Fukaya T, et al. PNAS 109: 11288-11293 (2012, MBL) | |
| Tsukamoto H, et al. Cancer Immunology 1: 64-76 (2013) | |
| Kimura K, et al. Infect Immun 81: 3825-3834 (2013) | |
| Yamazaki C, et al. J Immunol 190: 6071-6082 (2013) | |
| Shimizu K, et al. J Immunol 190: 5609-5619 (2013) | |
| Kobiyama K, et al. PNAS 111: 3086-3091 (2014) | |
| Ito M, et al. PLoS ONE 9: e110425 (2014, MBL) | |
| Sasaki K, et al. Nat. Commun. 6: 7484 (2015, MBL) | |
| Hanson MC, et al. Clin Invest 125: 2532-2546 (2015, MBLI) | |
| Rapaport AS, et al. Immunity 43:1112-1124 (2015, MBL) | |
| Toyota H, et al. Oncol Rep 33: 292-296 (2015, MBL) | |
| Takada K, et al. Nat Immunol 16: 1069–1076 (2015, MBL) | |
| Ito D, et al. J Immunol 195: 934-943 (2015, MBL) | |
| Seregin SS, et al. J Immunol 195: 1112-1120 (2015, MBLI) | |
| Pearce VQ, et al. J Immunol 195: 3206-3217 (2015, MBLI) | |
| Eikawa S, et al. PNAS 112: 1809-1814 (2015, MBL) | |
| Fu C, et al. PNAS 112: 2823-2828 (2015, MBLI) | |
| Kamimura D, et al. Int Immunol 28: 117-126 (2016, MBL) |
| H2-Kb | Garnett CT, et al. Clin Cancer Res 14: 3536–3544 (2008, BCI) |
| Quetglas JI, et al. J Immunol 190: 2994-3004 (2013, BCI) | |
| Cash H, et al. Oncotarget 6: 36400–36417 (2015) | |
| Melero I, et al. Cancer Res 75: 497-507 (2015, BCI) |
| H2-Db | Cheung K, et al PNAS 112: E5815-E5824 (2015, MBL) |
| H2-Db | Hodge JW, et al. J Immunol 174: 5994-6004 (2005, BCI) |
| Kudo-Saito C, et al. Clin Cancer Res 11: 2416-2426 (2005, BCI) | |
| Garnett CT, et al. Clin Cancer Res 14: 3536–3544 (2008, BCI) | |
| Loisel-Meyer S, et al. Mol Cancer Ther 8: 692–702 (2009, BCI) |
| Komine-Aizawa S et al. Cow milk exosomes activate NK cells and γδT cells in human PBMCs in vitro. Immunol Med. 43, 161-170 (2020)(PMID:32649844) | |
| Hojo MAet al. Identification of a genomic enhancer that enforces proper apoptosis induction in thymic negative selection. Nat Commun. 10, 2603 (2019)(PMID:31197149) | |
| Yoshiga Y, et al. Clin Exp Immunol. 164: 236–247 (2011) | |
| Horikoshi M, et al. PLoS One 7: e51215 (2012) | |
| Nakamura T, et al. J Control Release 171: 216–224 (2013) | |
| Sekiya T, et al. Nat Immunol 14: 230–237 (2013) | |
| Adachi K, et al. PLoS One 9: e96042 (2014) |
| Mamu-A*01 | Cecchinato V, et al. J. Immunol. 180: 5439-5447 (2008) |
| Jennifer N. Rainho JN, et al. J Virol 89: 10625-10636 (2015, MBL) |
| HLA-A:24*012 | Akiyama Y, et al. J Transl Med 3: 4-13 (2005) |
| Kozako T, et al. J Immunol 177: 5718-5726 (2006) | |
| Akimoto M, et al. J. Med Virol 79: 977-86 (2007) | |
| Tsuruma T, et al. J Transl Med 6: 24 (2008) | |
| Tsukahara T, et al. Cancer Sci 99: 368-375 (2008) | |
| Kozako T, et al. Leukemia 23: 375-382 (2009) | |
| Akiyama Y, et al. Anticancer Res 29: 647-655 (2009) | |
| Kameshima H, et al. Cancer Sci 102: 1181-1187 (2011) | |
| Kameshima H, et al. Cancer Sci 104: 124-129 (2013) | |
| Tezuka K, et al. Blood 123: 346-355 (2014) | |
| Koido S, et al. Clin Cancer Res 20: 4228-4239 (2014, MBL) | |
| Satomi F, et al. Int J Cancer Clin Res 2: 1-6 (2015, MBL) | |
| Tanaka T, et al. Cancer Sci. 106: 18-24 (2015) | |
| Najima Y, et al. Blood 127: 722-734 (2016, MBL) | |
| Murata K et al. OncoImmunology DOI:10.1080/2162402X.2016.1165376 | |
| H2-Kb | Asano J, et al. J Immunol 184: 736-745 (2010) |
| Wakita D, et al. Int Immunol 18: 425-434 (2006) | |
| Chamoto K, et al. Cancer Res 66: 1809-1817 (2006) | |
| Fujimura T, et al. Eur J Immunol 36: 3371-3380 (2006) |
